Astena Holdings Past Earnings Performance
Past criteria checks 4/6
Astena Holdings's earnings have been declining at an average annual rate of -9.5%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been declining at an average rate of 5.2% per year. Astena Holdings's return on equity is 7.1%, and it has net margins of 3.9%.
Key information
-9.5%
Earnings growth rate
-14.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | -5.2% |
| Return on equity | 7.1% |
| Net Margin | 3.9% |
| Last Earnings Update | 31 Aug 2024 |
Revenue & Expenses Breakdown
How Astena Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 53,387 | 2,091 | 14,620 | 0 |
| 31 May 24 | 53,218 | 2,093 | 14,248 | 0 |
| 29 Feb 24 | 52,625 | 1,617 | 14,163 | 0 |
| 30 Nov 23 | 51,984 | 1,162 | 14,044 | 0 |
| 31 Aug 23 | 53,382 | 182 | 13,653 | 0 |
| 31 May 23 | 51,559 | -580 | 13,750 | 0 |
| 28 Feb 23 | 50,136 | -76 | 13,608 | 0 |
| 30 Nov 22 | 49,636 | 579 | 13,541 | 0 |
| 31 Aug 22 | 55,523 | 1,212 | 13,975 | 0 |
| 31 May 22 | 61,007 | 1,693 | 13,848 | 0 |
| 28 Feb 22 | 67,632 | 1,787 | 13,751 | 0 |
| 30 Nov 21 | 72,322 | 1,736 | 13,494 | 0 |
| 31 Aug 21 | 71,504 | 1,543 | 13,416 | 0 |
| 31 May 21 | 70,758 | 2,366 | 12,940 | 0 |
| 28 Feb 21 | 67,745 | 2,185 | 12,299 | 0 |
| 30 Nov 20 | 65,341 | 1,983 | 11,813 | 0 |
| 31 Aug 20 | 62,815 | 1,957 | 11,940 | 0 |
| 31 May 20 | 61,425 | 1,234 | 11,537 | 0 |
| 29 Feb 20 | 61,463 | 1,380 | 11,281 | 0 |
| 30 Nov 19 | 61,647 | 1,533 | 11,056 | 0 |
| 31 Aug 19 | 62,327 | 1,537 | 10,910 | 0 |
| 31 May 19 | 62,113 | 1,688 | 10,790 | 0 |
| 28 Feb 19 | 61,285 | 1,718 | 10,674 | 0 |
| 30 Nov 18 | 60,083 | 1,414 | 10,594 | 0 |
| 31 Aug 18 | 59,321 | 1,418 | 10,417 | 0 |
| 31 May 18 | 58,368 | 991 | 10,352 | 0 |
| 28 Feb 18 | 57,849 | 745 | 10,282 | 0 |
| 30 Nov 17 | 57,387 | 1,241 | 10,108 | 0 |
| 31 Aug 17 | 56,633 | 567 | 9,950 | 0 |
| 31 May 17 | 56,320 | 780 | 9,870 | 0 |
| 28 Feb 17 | 55,459 | 508 | 9,861 | 0 |
| 30 Nov 16 | 55,121 | 8 | 9,892 | 0 |
| 31 Aug 16 | 54,654 | 222 | 9,918 | 0 |
| 31 May 16 | 54,750 | -258 | 9,851 | 0 |
| 29 Feb 16 | 55,174 | -138 | 9,761 | 0 |
| 30 Nov 15 | 55,422 | -143 | 9,923 | 0 |
| 31 Aug 15 | 55,693 | 148 | 9,923 | 0 |
| 31 May 15 | 54,925 | 392 | 10,202 | 0 |
| 28 Feb 15 | 54,602 | 475 | 10,171 | 0 |
| 30 Nov 14 | 54,145 | 496 | 9,966 | 0 |
| 31 Aug 14 | 53,648 | 462 | 9,820 | 0 |
| 31 May 14 | 53,528 | 721 | 9,489 | 0 |
| 28 Feb 14 | 53,091 | 783 | 9,380 | 0 |
| 30 Nov 13 | 52,465 | 744 | 9,488 | 0 |
Quality Earnings: 8095 has high quality earnings.
Growing Profit Margin: 8095's current net profit margins (3.9%) are higher than last year (0.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8095's earnings have declined by 9.5% per year over the past 5 years.
Accelerating Growth: 8095's earnings growth over the past year (1048.9%) exceeds its 5-year average (-9.5% per year).
Earnings vs Industry: 8095 earnings growth over the past year (1048.9%) exceeded the Pharmaceuticals industry 14.4%.
Return on Equity
High ROE: 8095's Return on Equity (7.1%) is considered low.